LifeStance Health Group (NASDAQ:LFST) Upgraded at Barclays

Barclays upgraded shares of LifeStance Health Group (NASDAQ:LFST) to a strong-buy rating in a research note released on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the company. Wall Street Zen downgraded LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. BTIG Research increased their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday. BMO Capital Markets began coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.86.

LifeStance Health Group Trading Up 4.2%

Shares of NASDAQ:LFST opened at $6.75 on Monday. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.30. The company’s 50 day moving average is $5.79 and its two-hundred day moving average is $5.32. The company has a market cap of $2.63 billion, a PE ratio of -225.00 and a beta of 1.13. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The company’s revenue was up 16.3% compared to the same quarter last year. Equities analysts predict that LifeStance Health Group will post -0.18 earnings per share for the current fiscal year.

Insider Activity at LifeStance Health Group

In other news, insider Lisa K. Miller sold 57,240 shares of LifeStance Health Group stock in a transaction on Friday, November 21st. The shares were sold at an average price of $6.43, for a total value of $368,053.20. Following the transaction, the insider directly owned 261,292 shares of the company’s stock, valued at $1,680,107.56. The trade was a 17.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of LFST. Park Edge Advisors LLC acquired a new stake in shares of LifeStance Health Group during the second quarter worth about $52,000. Bayesian Capital Management LP purchased a new stake in LifeStance Health Group during the 2nd quarter valued at approximately $52,000. Public Employees Retirement System of Ohio acquired a new stake in LifeStance Health Group during the 2nd quarter worth approximately $70,000. Blair William & Co. IL purchased a new position in shares of LifeStance Health Group in the 2nd quarter valued at approximately $70,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of LifeStance Health Group in the third quarter valued at approximately $72,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.